Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to…
News
SpringWorks Therapeutics announced new collaborations with two companies, Pfizer and Janssen, to investigate its oral therapy candidate nirogacestat in combination with BCMA-targeting agents…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CellProtect, an investigational therapy for multiple myeloma…
An independent data monitoring committee has recommended that the GENESIS Phase 3 trial evaluating motixafortide (formerly BL-8040), as a means to improve stem cell…
CLR 131, Cellectar Biosciences’ lead experimental candidate, resulted in a 40% response rate among people with multiple myeloma who failed to respond…
The cast of the hit sitcom “Everybody Loves Raymond” reunited online to honor former co-star Peter Boyle for the International Myeloma Foundation’s (IMF)…
First-line maintenance therapy with Darzalex (daratumumab) significantly delays disease progression or death in adults with multiple myeloma who responded to autologous stem cell transplant (ASCT), according to data…
Oncopeptides soon will seek conditional approval of melflufen (melphalan flufenamide) in the EU for the treatment of relapsed or refractory multiple myeloma. The pharmaceutical…
After first rejecting a Sarclisa (isatuximab) triple combination therapy due to cost-effectiveness concerns, the U.K.’s National Institute for Health and Care…
NexImmune has dosed the first patient participating in its Phase 1/2 trial of NEXI-002, the company’s investigational T-cell therapy for multiple…
